Weed Inc is working on or planning for several different business opportunities in the cannabis and hemp field, including, but not limited to both indoor and outdoor grows, cultivations, and harvest for research, product development, processing, and manufacturing of both Pharma and non-Pharma products, services, therapeutics, and treatments on a basis for both the Medical Cannabis and Hemp global market space... Show more
On April 21, 2025, the Stochastic Oscillator for BUDZ moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 87 instances where the indicator left the oversold zone. In of the 87 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Moving Average Convergence Divergence (MACD) for BUDZ just turned positive on April 17, 2025. Looking at past instances where BUDZ's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
BUDZ moved above its 50-day moving average on April 23, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BUDZ advanced for three days, in of 169 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on April 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BUDZ as a result. In of 143 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BUDZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BUDZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BUDZ's P/B Ratio (10000.000) is very high in comparison to the industry average of (61.171). P/E Ratio (0.000) is within average values for comparable stocks, (90.174). BUDZ's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (20.123).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BUDZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry PharmaceuticalsOther
A.I.dvisor tells us that BUDZ and CBWTF have been poorly correlated (+14% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BUDZ and CBWTF's prices will move in lockstep.
Ticker / NAME | Correlation To BUDZ | 1D Price Change % | ||
---|---|---|---|---|
BUDZ | 100% | +1.00% | ||
CBWTF - BUDZ | 14% Poorly correlated | -0.78% | ||
BOIRF - BUDZ | 7% Poorly correlated | N/A | ||
CANN - BUDZ | 7% Poorly correlated | -0.27% | ||
BIOYF - BUDZ | 6% Poorly correlated | +0.27% | ||
BSPK - BUDZ | 2% Poorly correlated | +33.16% | ||
More |